Determinants of Diagnostic Performance Of [F-18]Fluorodeoxyglucose Positron Emission Tomography for Axillary Staging in Breast Cancer
- 1 November 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 236 (5) , 619-624
- https://doi.org/10.1097/00000658-200211000-00012
Abstract
Objective To prospectively investigate determinants of the accuracy of staging axillary lymph nodes in breast cancer using [F-18]fluorodeoxyglucose positron emission tomography (FDG PET). Methods Patients with primary operable breast cancer underwent FDG PET of the chest followed by sentinel node biopsy (SNB, n = 47) and/or complete axillary lymph node dissection (ALND, n = 23). PET scans were independently interpreted by three observers in a blinded fashion with respect to the FDG avidity of the primary tumor and the axillary status. The results were compared to histopathological analyses of the axillary lymph nodes. Clinicians were blinded to the PET results. Results Axillary lymph node specimens and FDG PET scans were evaluated in 70 patients (59% cT1). Overall, 32 (46%) had lymph node metastases as established by SNB (18/47) or ALND (14/23), 20 of which were confined to a single node. The overall sensitivity of FDG PET was 25%, with a specificity of 97%. PET results were false-negative in all 18 positive SNBs and true-positive in 8/14 in the ALND group. The performance of FDG PET depended on the axillary tumor load and the FDG avidity of the primary tumor. Intense uptake in the primary tumor was found in only 57% of the patients, and this was independent of the size. There was excellent interobserver agreement of visual assessment of FDG uptake in primary tumor and axillary lymph nodes. Conclusions The sensitivity of FDG PET to detect occult axillary metastases in operable breast cancer was low, and it was a function of axillary tumor load and FDG avidity of the primary tumor. Even though the clinical relevance of occult disease detected by SNB needs to be confirmed, it is suggested that FDG PET in these patients should be focused on exploiting its nearly perfect specificity and the potential prognostic relevance of variable FDG uptake.Keywords
This publication has 24 references indexed in Scilit:
- Comparison of Attenuation-corrected and Non-corrected FDG-PET Images for Axillary Nodal Staging in Newly Diagnosed Breast CancerMolecular Imaging & Biology, 2002
- Re: Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography: Clinical Evaluation and Alternative ManagementJNCI Journal of the National Cancer Institute, 2001
- Sentinel node investigation in breast cancer: detailed analysis of the yield from step sectioning and immunohistochemistryJournal of Clinical Pathology, 2001
- Staging of the Axilla in Breast CancerAnnals of Surgery, 1998
- Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.Radiology, 1998
- Sentinel Lymph Node Biopsy in Breast Cancer: Guidelines and Pitfalls of Lymphoscintigraphy and Gamma Probe DetectionJournal of the American College of Surgeons, 1998
- Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.Radiology, 1997
- Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistryEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Assessment of Axillary Lymph Node Involvement in Breast Cancer Patients With Positron Emission Tomography Using Radiolabeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucoseJNCI Journal of the National Cancer Institute, 1996
- Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.Radiology, 1993